Compare · DFTX vs MTEX
DFTX vs MTEX
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Mannatech Incorporated (MTEX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and MTEX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.95B, about 312.9x MTEX ($15.8M).
- Over the past year, DFTX is up 279.6% and MTEX is down 12.6% - DFTX leads by 292.2 points.
- DFTX has been more active in the news (14 items in the past 4 weeks vs 2 for MTEX).
- DFTX has more recent analyst coverage (7 ratings vs 0 for MTEX).
PerformanceDFTX+279.59%MTEX-12.61%
2025-09-16+0.00%2026-09-15
- Company
- Definium Therapeutics Inc.
- Mannatech Incorporated
- Price
- $36.82-8.23%
- $8.11+0.37%
- Market cap
- $4.95B
- $15.8M
- 1M return
- -13.54%
- +66.53%
- 1Y return
- +279.59%
- -12.61%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 14
- 2
- Recent ratings
- 7
- 0
MTEX
Mannatech Incorporated
Mannatech, Incorporated operates as a health and wellness company worldwide. It develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management products. The company primarily sells its products directly, as well as through network marketing channels and a website. Mannatech, Incorporated was founded in 1993 and is headquartered in Flower Mound, Texas.
Latest DFTX
- Chief Executive Officer Barrow Robert was granted 750,000 shares, increasing direct ownership by 50% to 2,244,640 units (SEC Form 4)
- Chief Legal Officer Sullivan Mark was granted 125,000 shares, increasing direct ownership by 33% to 508,279 units (SEC Form 4)
- Chief Financial Officer Roberts Brandi was granted 125,000 shares, increasing direct ownership by 46% to 397,905 units (SEC Form 4)
- Chief Commercial Officer Wiley Matthew T. was granted 125,000 shares, increasing direct ownership by 53% to 362,133 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel was granted 200,000 shares, increasing direct ownership by 33% to 803,699 units (SEC Form 4)
- Definium Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest MTEX
- Mannatech Incorporated filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Mannatech Announces Retirement of J. Stanley Fredrick from the Board and Appointment of Robert Toth as Chairman of the Board
- Mannatech Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Mannatech Incorporated
- Mannatech Reports Financial Results for Second Quarter 2026
- SEC Form 4 filed by Chief Financial Officer Haider Yasir
- SEC Form 3 filed by new insider Haider Yasir
- Mannatech Incorporated filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Mannatech Announces Appointment of Yasir Haider as Chief Financial Officer
- SEC Form 4 filed by Director Toth Robert